Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Monoamine oxidase B | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | Get druggable targets OG5_130722 | All targets in OG5_130722 |
Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | Get druggable targets OG5_130722 | All targets in OG5_130722 |
Mycobacterium tuberculosis | Probable flavin-containing monoamine oxidase AofH (amine oxidase) (MAO) | Get druggable targets OG5_130722 | All targets in OG5_130722 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Dictyostelium discoideum | hypothetical protein | Monoamine oxidase B | 520 aa | 539 aa | 22.3 % |
Dictyostelium discoideum | amine oxidase | Monoamine oxidase B | 520 aa | 489 aa | 29.0 % |
Dictyostelium discoideum | hypothetical protein | Monoamine oxidase B | 520 aa | 538 aa | 21.0 % |
Onchocerca volvulus | Mitochondrial fission process protein 1 homolog | Monoamine oxidase B | 520 aa | 469 aa | 22.0 % |
Brugia malayi | amine oxidase, flavin-containing family protein | Monoamine oxidase B | 520 aa | 479 aa | 21.7 % |
Dictyostelium discoideum | hypothetical protein | Monoamine oxidase B | 520 aa | 531 aa | 23.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | Transitional endoplasmic reticulum ATPase, putative,valosin-containing protein homolog | 0.0816 | 0.9326 | 0.5 |
Schistosoma mansoni | cell division control protein 48 aaa family protein | 0.0816 | 0.9326 | 0.9122 |
Mycobacterium ulcerans | ATPase | 0.0515 | 0.4742 | 1 |
Trypanosoma cruzi | Valosin-containing protein, putative | 0.0816 | 0.9326 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0504 | 0.4584 | 1 |
Giardia lamblia | AAA family ATPase | 0.0515 | 0.4742 | 0.5 |
Entamoeba histolytica | transitional endoplasmic reticulum ATPase, putative | 0.0816 | 0.9326 | 0.5 |
Brugia malayi | vesicle-fusing ATPase | 0.0504 | 0.4584 | 1 |
Echinococcus multilocularis | transitional endoplasmic reticulum atpase | 0.086 | 1 | 1 |
Schistosoma mansoni | cell division control protein 48 aaa family protein | 0.086 | 1 | 1 |
Plasmodium falciparum | cell division cycle protein 48 homologue, putative | 0.0816 | 0.9326 | 0.5 |
Trypanosoma brucei | Valosin-containing protein | 0.0816 | 0.9326 | 0.5 |
Onchocerca volvulus | Transitional endoplasmic reticulum ATPase homolog | 0.086 | 1 | 0.5 |
Trichomonas vaginalis | spermatogenesis associated factor, putative | 0.086 | 1 | 1 |
Brugia malayi | valosin containing protein | 0.0504 | 0.4584 | 1 |
Toxoplasma gondii | cell division protein CDC48AP | 0.0515 | 0.4742 | 0.0000097958 |
Toxoplasma gondii | cell division protein CDC48CY | 0.086 | 1 | 1 |
Entamoeba histolytica | cdc48-like protein, putative | 0.0816 | 0.9326 | 0.5 |
Plasmodium vivax | cell division cycle protein 48 homologue, putative | 0.0816 | 0.9326 | 1 |
Mycobacterium tuberculosis | Putative conserved ATPase | 0.0515 | 0.4742 | 1 |
Loa Loa (eye worm) | vesicle-fusing ATPase | 0.0504 | 0.4584 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 7.4 | Inhibition of Sprague-Dawley rat MAO-B using Kynuramine as substrate assessed as formation of 4-hydroxyquinoline preincubated for 5 mins prior to substrate addition measured for 5 mins by spectrophotometry | ChEMBL. | 24231308 |
IC50 (binding) | = 7.4 | Inhibition of Sprague-Dawley rat MAO-B in brain mitochondrial homogenate assessed as 4-hydroxyquinoline by spectrophotometric method | ChEMBL. | 25462230 |
Inhibition (binding) | = 0 % | Inhibition of Sprague-Dawley rat MAO-A using Kynuramine as substrate assessed as formation of 4-hydroxyquinoline at 10 uM preincubated for 5 mins prior to substrate addition measured for 5 mins by spectrophotometry | ChEMBL. | 24231308 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.